Immunome (IMNM) Total Current Liabilities (2019 - 2026)

Immunome has reported Total Current Liabilities for 8 years, with the latest figure at $27.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 10.99% year-over-year to $27.4 million; the trailing twelve-month figure through Mar 2026 stood at $27.4 million (down 10.99% YoY), and the FY2025 full-year result was $45.0 million, down 17.16% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $27.4 million, down from $45.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $54.3 million in Q4 2024, with the low at $7.3 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $26.5 million across 5 years, with a median of $26.4 million in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 213.62% — and 2025, when it plunged 42.66%.
• Immunome's Total Current Liabilities stood at $7.3 million in 2022, then soared by 197.76% to $21.8 million in 2023, then surged by 148.78% to $54.3 million in 2024, then declined by 17.16% to $45.0 million in 2025, then plunged by 39.07% to $27.4 million in 2026.
• The last three Total Current Liabilities figures came in at $27.4 million (Q1 2026), $45.0 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.